Key result
Venous thromboembolism management requires careful risk stratification and monitoring for complications from both the disease and therapies like anticoagulants or inferior vena cava filters.
This review highlights the importance of risk stratification, prognostication, and monitoring for complications in patients with venous thromboembolism receiving therapies such as anticoagulants or IVC filters.
Answers are grounded in this paper and cite their sources.
Supports vigilant VTE monitoring to avert therapy harms; leaves open optimal stratification protocols pending prospective trials.
Venous thromboembolism (VTE) can present in a variety of different clinical settings and in a diverse, comorbid patient population, both of which will guide the clinician toward the appropriate therapeutic response. Patients who present with pulmonary embolism are at risk for hemodynamic instability, recurrence of VTE, cardiac comorbidities, and increased risk of overall mortality. Prognostication models have been clinically validated for risk stratification and prediction of mortality. Similar to pulmonary embolism, patients with deep vein thrombosis carry a higher risk of VTE recurrence and cardiac comorbidities. Consequently, VTE can be treated by a variety of methods such as anticoagulants or inferior vena cava filters, which bear their own risks and benefits. It is imperative that clinicians monitor patients for complications from VTE and the chosen therapy.
No takes yet. Share an insight, caveat, or question.
Naddour et al. (2017) conducted a review in Venous thromboembolism (VTE). Venous thromboembolism management requires careful risk stratification and monitoring for complications from both the disease and therapies like anticoagulants or inferior vena cava filters.
Synapse has enriched 10 related papers. Consider them for comparative context: